Compare ProShares Ultra QQQ ETF (QLD) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ProShares Ultra QQQ ETF vs BIO-TECHNE Corp — how do they compare? ProShares Ultra QQQ ETF trades at $99.14 (market cap $15.83B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.37B). The key difference: ProShares Ultra QQQ ETF is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while ProShares Ultra QQQ ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold ProShares Ultra QQQ ETF for 37 Days and BIO-TECHNE Corp for 63 Days on average.
| QLD | TECH | |
|---|---|---|
Market Cap | $15.83B | $11.37B |
Volume | 3,097,438 | 3,153,511 |
Sector | Leveraged / Inverse | Health |
52-Week High | $100.77 | $72.61 |
52-Week Low | $57.16 | $43.31 |
Typical Hold Time | 37 Days | 63 Days |
Enterprise Value | — | $11.40B |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
QLD (ProShares Ultra QQQ ETF) trades at $100.23, down 0.54% on the day, with technical indicators showing a bullish moving average signal but overbought RSI conditions. The ETF provides 2x leveraged exposure to the Nasdaq-100 index, offering amplified returns during market rallies while being less volatile than 3x leveraged alternatives. Recent institutional buying activity and media coverage highlight continued investor interest in leveraged tech exposure.
The outlook for QLD remains tied to Nasdaq-100 performance, with technical support at $99 and resistance at $101. While the bullish moving average alignment suggests upward momentum, overbought RSI levels indicate potential near-term consolidation. Key risks include market volatility, Federal Reserve policy impacts, and the inherent leverage decay characteristic of daily reset ETFs.
TECH trades at $72.53, near its 52-week high of $72.70, with a bullish technical signal and strong institutional interest. Recent earnings show mixed results, beating in Q2 2026 but missing in Q1. The company maintains solid profitability with a 65.77% gross margin, though net income declined to $73.40M in 2025. Shareholders approved an acquisition by Merck KGaA at $73.00 per share, a key near-term catalyst.
Outlook is positive due to the pending acquisition, but risks include execution challenges and valuation concerns with a high P/E of 62.53. Analyst consensus is divided with 46% buy ratings, suggesting cautious optimism. The stock offers limited upside to the acquisition price, making it suitable for event-driven investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ProShares Ultra QQQ ETF
QLD is a leveraged ETF that seeks daily investment results corresponding to 200% of the daily performance of the NASDAQ-100 Index. It achieves 2x leverage by investing in financial instruments such as swaps and is designed as a tactical trading tool for investors with a bullish (long) view on the NASDAQ-100. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment.
Read more on QLD →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
